Merck tops third-quarter estimates as Keytruda, Gardasil outperform
Merck reported Q3 revenue of $18.1B, beating estimates of $17.3B. Keytruda sales rose 6% to $8.6B, and Gardasil sales increased 14% to nearly $2B. Merck raised its full-year revenue forecast to $66.8B-$67.3B and adjusted earnings outlook to $2.77-$2.82 per share. The company has been diversifying its portfolio, with Winrevair sales up 94% to $694M. Merck shares are up 34% this year.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise suggest continued revenue momentum, but future patent cliffs remain a risk.
Market read
Merck's earnings beat and raised outlook are likely to lift the stock and positively influence the broader healthcare sector.
What to watch
Potential competitive pressure from biosimilars could temper long-term growth.
Background
Merck's Q3 results highlight strong performance of Keytruda and Gardasil, with early purchases boosting sales.
Ticker impact
Merck reported Q3 earnings beating estimates and raised full-year revenue and earnings guidance.
upward pressure as investors price in stronger revenue and earnings outlook
Beat on revenue and EPS, plus raised guidance, typically drive buying interest.
Market effects
Boosts biotech/pharma sector sentiment, especially peers with immunotherapy pipelines.
Supports US large-cap health care index performance.
Reinforces confidence in US pharma earnings outlook globally.
Counterpoint
Some investors may worry about upcoming patent expirations for Keytruda starting 2028.
Key entities
- companyMerck
US pharmaceutical giant reporting Q3 results.
